Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sanofi-Lilly Settlement Paves Way For Biosimilar Lantus

This article was originally published in Scrip

Executive Summary

A potential launch of Eli Lilly & Co.'s copycat version of Sanofi's blockbuster Lantus (insulin glargine) in 2016 will put pressure on the entire insulin category, including new drugs like Novo Nordisk AS's Tresiba (insulin degludec) and Sanofi's own follow-on Toujeo.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register